Related Experiment Video

Updated: May 14, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

G Protein-Coupled Receptors in cancer: biochemical interactions and drug design

Yves Audigier1, François-Xavier Picault, Carline Chaves-Almagro

  • 1Cancer Research Center of Toulouse, INSERM U1037-Université Paul Sabatier Toulouse III, Toulouse, France.

Progress in Molecular Biology and Translational Science
|February 19, 2013
PubMed

Insights

G Protein-Coupled Receptors (GPCRs) can act as proto-oncogenes, driving cancer through altered interactions and signaling. Targeting these complex GPCR interactions offers promising new avenues for cancer therapy development.

Area of Science:

  • Molecular Biology
  • Oncology
  • Pharmacology

Background:

  • G Protein-Coupled Receptors (GPCRs) are the largest membrane receptor family, known for signal transduction.
  • GPCRs and heterotrimeric G proteins can function as proto-oncogenes, promoting cell transformation.
  • Overexpression or activating mutations in GPCRs confer oncogenic properties.

Purpose of the Study:

  • To review the link between GPCR biochemical interactions and oncogenic properties.
  • To explore the potential of targeting GPCR interactions for cancer therapy.

Main Methods:

  • Review of literature focusing on GPCRs, signal transduction, and cancer biology.
  • Analysis of GPCR dimerization and multiprotein complex formation in oncogenesis.
  • Examination of drug design strategies targeting GPCR interactions.

Main Results:

  • Altered GPCR interactions (e.g., dimerization, complex formation) contribute to uncontrolled cell proliferation and malignancy.
  • Deregulation of GPCR-mediated transduction cascades promotes tumorigenicity.
  • Targeting these complex GPCR interactions shows promise for novel cancer therapeutics.

Conclusions:

  • GPCRs play a significant role in cancer development through aberrant signaling and interactions.
  • Drug design strategies focused on these complex interactions represent a promising frontier in oncology.

More Related Videos

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

Related Concept Videos

G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...